Clopidogrel resistance

Clopidogrel resistance is a condition in which the drug clopidogrel is less effective than normal in people who are treated with it. Clopidogrel (also known as Plavix) is an antiplatelet drug, which means that it prevents blood cells called platelets from sticking together (aggregating) and forming blood clots. This drug is typically given to prevent blood clot formation in individuals with a history of stroke; heart attack; a blood clot in the deep veins of the arms or legs (deep vein thrombosis); or plaque buildup (atherosclerosis) in the blood vessels leading from the heart, which are opened by placement of a small thin tube (stent).

People with clopidogrel resistance who receive clopidogrel are at risk of serious, sometimes fatal, complications. These individuals may have another heart attack or stroke caused by abnormal blood clot formation; those with stents can develop blood clots (thromboses) within the stents, impeding blood flow.

People with clopidogrel resistance can be divided into two categories: intermediate metabolizers and poor metabolizers. Intermediate metabolizers are able to process some clopidogrel, so they receive partial benefit from the treatment but are not protected from developing a harmful blood clot. Poor metabolizers process little or no clopidogrel, so they receive very limited benefit from the treatment and are at risk of forming a harmful blood clot.

Clopidogrel resistance does not appear to cause any health problems other than those associated with clopidogrel drug treatment.

Frequency

Clopidogrel resistance is a common condition, and its incidence can vary depending on ancestry. About half of individuals with Asian ancestry have clopidogrel resistance, with 10 percent of these individuals classified as poor metabolizers. Among people from western countries, nearly 30 percent are estimated to have clopidogrel resistance, with about 3 percent classified as poor metabolizers.

Causes

Many genes are involved in converting clopidogrel to its active form and in determining the drug's effects in the body. The \textit{CYP2C19} gene is particularly important for the activation of clopidogrel, and certain common variations (polymorphisms) in this gene have been associated with clopidogrel resistance. \textit{CYP2C19} gene polymorphisms account for most of the variation in clopidogrel activation due to genetic factors. Polymorphisms in other genes likely have smaller effects on clopidogrel activation.
The CYP2C19 gene provides instructions for making an enzyme that is found primarily in liver cells. It is active in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport. The CYP2C19 enzyme plays a role in the processing of many drugs, including clopidogrel. The CYP2C19 enzyme helps to convert clopidogrel to its active form, which is necessary for the drug to function in the body. In its active form, clopidogrel prevents (inhibits) the function of a receptor protein known as P2RY12 that is found on the surface of platelets. During clot formation, the P2RY12 receptor protein helps platelets cluster together to form a clot to seal off damaged blood vessels and prevent blood loss. By inhibiting the function of the P2RY12 receptor, clopidogrel decreases the formation of blood clots, including clots that can cause heart attack, stroke, and deep vein thrombosis.

The two most common CYP2C19 gene polymorphisms associated with clopidogrel resistance (known as CYP2C19*2 and CYP2C19*3) result in the production of a nonfunctional CYP2C19 enzyme that cannot convert clopidogrel to its active form. Without active clopidogrel to interfere, the P2RY12 receptor continues to promote platelet aggregation and blood clot formation, which can lead to heart attacks, strokes, and thromboses in individuals with a history of these conditions.

In addition to changes in specific genes, many other factors, including gender, age, weight, diet, and other medications, play a role in how the body reacts to clopidogrel.

**Inheritance Pattern**

Clopidogrel resistance is inherited in an autosomal codominant pattern. Codominance means that two different versions of the gene are active (expressed), and both versions influence the genetic trait. Some people with clopidogrel resistance have a reduced ability to convert the drug to its active form because of a polymorphism in one copy of the CYP2C19 gene that results in decreased enzyme activity. These individuals are described as intermediate metabolizers. Other individuals with clopidogrel resistance convert very little or none of the drug to its active form because of polymorphisms in both copies of the CYP2C19 gene, which results in a lack of enzyme activity. These individuals are described as poor metabolizers.

It is important to note that not all individuals with CYP2C19 gene mutations have clopidogrel resistance. These individuals who are at increased risk for developing clopidogrel resistance may or may not have a bad reaction when treated with the drug.

**Other Names for This Condition**

- CYP2C19-related poor drug metabolism
- poor metabolism of clopidogrel
- resistance to clopidogrel
Diagnosis & Management

Genetic Testing Information

- What is genetic testing?
  /primer/testing/genetictesting

- Genetic Testing Registry: Clopidogrel response

- Genetic Testing Registry: CYP2C19-related poor drug metabolism

Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22clopidogrel+resistance%22+OR+%22poor+metabolism+of+clopidogrel%22

Other Diagnosis and Management Resources

- American Society of Hematology: Antithrombotic Therapy
  https://www.hematology.org/About/History/50-Years/1523.aspx

- MedlinePlus Encyclopedia: Clopidogrel (Plavix)
  https://medlineplus.gov/ency/patientinstructions/000100.htm

- PharmGKB
  https://www.pharmgkb.org/guidelineAnnotation/PA166104948

Additional Information & Resources

Health Information from MedlinePlus

- Drugs & Supplements: Clopidogrel
  https://medlineplus.gov/druginfo/meds/a601040.html

- Encyclopedia: Clopidogrel (Plavix)
  https://medlineplus.gov/ency/patientinstructions/000100.htm

- Health Topic: Bleeding
  https://medlineplus.gov/bleeding.html

- Health Topic: Blood Clots
  https://medlineplus.gov/bloodclots.html

- Health Topic: Blood Thinners
  https://medlineplus.gov/bloodthinners.html

- Medical Tests: Pharmacogenetic Tests
  https://medlineplus.gov/lab-tests/pharmacogenetic-tests/
Genetic and Rare Diseases Information Center

- CYP2C19-related poor drug metabolism

Educational Resources

- American Society of Hematology: Blood Clots
  https://www.hematology.org/Patients/Clots/

- FDA Medication Guide

- MalaCards: clopidogrel resistance
  https://www.malacards.org/card/clopidogrel_resistance

  https://www.merckmanuals.com/home/blood-disorders/blood-clotting-process/how-blood-clots

- National Health Service (NHS): Antiplatelets, Clopidogrel (UK)
  https://www.nhs.uk/medicines/clopidogrel/

- Orphanet: Resistance to clopidogrel
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=240935

Patient Support and Advocacy Resources

- National Blood Clot Alliance
  https://www.stoptheclot.org/

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28clopidogrel+resistance%5BTIAB%5D+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1080+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- DRUG METABOLISM, POOR, CYP2C19-RELATED
  http://omim.org/entry/609535
Sources for This Summary

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23165865

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25877345

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23698643
Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748366/

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20585015

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22804232

Reprinted from Genetics Home Reference:

Reviewed: December 2015
Published: March 3, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services